49 results about "Etiracetam" patented technology

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.

The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam to SV2 proteins, including SV2A. Additionally, the present invention provides biotinylated ligands as a tool to screen chemical libraries and characterize the SV2 proteins. Further, the present invention provides a method of solubilizing and purifying functionally active membrane associated proteins, such as SV2.

The invention discloses a new synthesizing technique of chiral drug (S)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide ( left Piracetam) intermediate (S)-(+)-2-aminobutanamide hydrochlorate, which comprises the following steps: adopting 2-brobutyrate as initial raw material; aminating; esterifying; ammonolyzing; detaching; looping; obtaining the object compound; making mixed rotary free alkaline (+-)-2-aminobutanamide; adopting half-quantum resolution method to connect chemical detaching salt to evolve salt; removing the detaching agent through alkalization; obtaining the (S)-(+)-2-aminobutanamidehydrochlorate with optical activity; using the mother liquor to make the product. The invention improves the receiving rate and saves the cost of raw material with simply technical operation and low cost, which resolves the resolved mother liquor after racemic action again to reduce the pollution of environment, therefore fitting for industrialized manufacturing.

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam. A process for preparing the dosage form is also provided

The present invention discloses a high dose rapidly dispersing three-dimensional printing dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water in a time period of less than about 10 seconds. Also disclosed are methods of making the dosage forms and methods of treating diseases, conditions or disorders that are therapeutically responsive to levetiracetam. The invention also provides methods for preparing the dosage forms.

The invention belongs to the technical field of pharmaceutical preparations, in particular to a levetiracetam tablet and a preparation method thereof. The preparation method comprises the following steps: step 1: sieve levetiracetam, hydroxypropyl cellulose, croscarmellose sodium and part of colloidal silicon dioxide together for later use; step 2: sift the After the granulation materials are mixed, magnesium stearate is added and mixed evenly to obtain a premixed powder; step 3: the premixed powder in step 2 is placed in dry granulation and granulated to obtain a mixture of granules and powder; step 4: The mixture of granules and powder after the granulation in Step 3 is mixed with the remaining colloidal silicon dioxide and then compressed into tablets; Step 5: Coating. The preparation method provided by the invention has the advantages of simple technological process, strong operability, low production cost and stability.

The invention discloses a preparation method for a levetiracetam intermediate (S)-alpha-ethyl-2-oxo-1-pyrrolidine acetic acid, which takes (RS)-alpha-ethyl-2-oxo-1- pyrrolidine acetic acid as the starting material and takes (R)-alpha-methyl benzylamine as resolving agent to get the product through resolving in resolving solvent. The invention is characterized in that the resolving solvent can be C1-C7 ketones, C1-C7 alcohols, C1-C4 esters or the mixture of the solvents. In addition, the by-product (R)-alpha-ethyl -2 - oxo -1 - pyrrolidine acetic acid can be recovered through racemization under the effect of alkali so as to regain the (RS)-alpha-ethyl -2-oxo-1- pyrrolidine acetic acid. Compared with the existing invention, the preparation method of the invention has the advantages that during resolving, the solvent selected for the compound (RS)-alpha-ethyl -2-oxo -1 - pyrrolidine acetic acid has high resolving efficiency and small toxicity; the resolving salt only needs to be refined once, so that the optical purity of (S)-alpha-ethyl -2-oxo -1 - pyrrolidine acetic acid can meet the requirement (alpha<20>D is equal to -25.0 plus or minus 1 degree (C is equal to 1, acetone)). In addition, the racemic recovery of the compound (R)-alpha-ethyl -2-oxo-1-pyrrolidine acetic acid can reduce environmental pollution and decrease the cost of the product.

The invention discloses a preparation method of (S)-2-aminobutanamide as a key intermediate for levetiracetam, which belongs to the technical field of drug intermediate synthesis. According to the preparation method disclosed by the invention, a compound 1 undergoes ammonolysis reaction in C1-C3 alkyl alcohol, vacuum concentration is carried out until a dry state is formed after the reaction is complete, an alcoholic solvent is added, ammonia is further injected for freeing, an alcoholic solvent is added for clarification by dissolution after filtration and concentration, crystals are grown after an acidic alcoholic solvent is dripped for salification, a compound 2 is obtained by preparation and purification, wherein X is hydrochloric acid, hydrobromic acid or methanesulfonic acid. The preparation method disclosed by the invention is simple and effective, yield and purity are greatly increased, molar yield is higher than 90 percent, purity is higher than 99.5 percent, a high-quality intermediate is provided for the subsequent preparation of the levetiracetam, the preparation method does not have the step of chiral resolution, and adopts only one type of solvent, recovery is simple,three types of wastes are fewer, and the preparation method meets the requirement of industrial production.

The invention provides a levetiracetam sustained-release tablet and a preparation method thereof. In the present invention, after drying the required raw materials and auxiliary materials of the sustained-release tablet, they are divided into a blank layer (according to the batching ratio of the blank layer, the slow-release material and adhesive are mixed uniformly and sieved) and the slow-release layer ( Take levetiracetam, sustained-release material and adhesive according to the batching ratio of the sustained-release layer, mix them uniformly according to the method of equal increase, and weigh the granules respectively, add lubricant, mix well, and place in a double-layer Tablets are made in the two hoppers of the tablet press.

The invention discloses a method for detecting devetiracetam (R-isomer) from levetiracetam injection, and adopts high performance liquid chromatography to carry out qualitative or / and quantitative detection of the R-isomer, The detection condition of liquid chromatography comprises: chromatographic column: cellulose-three (3,5-dichlorophenyl carbamate) silica gel column; Mobile phase: n-hexane, dehydrated alcohol; Wherein, n-hexane (vol.% ): absolute ethanol (vol.%)=90~70: 10~30; the mobile phase adopts isocratic elution. The method of the invention can effectively detect the levetiracetam in the levetiracetam injection, and has specificity and stability indicating ability. Moreover, the levetiracetam injection can be directly diluted and tested without pretreatment of samples, which is convenient and fast; the detection limit of the method of the invention reaches 0.003%, and the quantification limit reaches 0.005%, which is accurate and sensitive.